Literature DB >> 10225458

Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer.

J Kleeff1, T Kusama, D L Rossi, T Ishiwata, H Maruyama, H Friess, M W Büchler, A Zlotnik, M Korc.   

Abstract

Macrophage Proinflammatory Human Chemokine-3alpha (Mip-3alpha/LARC/Exodus) belongs to a large family of chemotactic cytokines, which participate in directing inflammatory cell migration and in modulating angiogenesis. Mip-3alpha signals through a recently identified G-protein linked 7-transmembrane receptor, CCR6. In this study, we have characterized the expression of Mip-3alpha and CCR6 in 12 normal and 16 cancerous human pancreatic tissues and in 4 cultured pancreatic cancer cell lines, and assessed the effects of Mip-3alpha on growth and invasion of these cell lines. Pancreatic cancer tissues markedly overexpressed Mip-3alpha in comparison with normal pancreatic samples. By in situ hybridization Mip-3alpha and CCR6 mRNA moieties were present in cancer cells within the tumors. In addition, Mip-3alpha was abundant in the macrophages infiltrating the tumor mass. Mip-3alpha and its receptor CCR6 were expressed in all 4 tested pancreatic cancer cell lines. Mip-3alpha stimulated the growth of one cell line, enhanced the migration of another cell line, and was without effect in the other 2 cell lines. Together, our findings suggest that Mip-3alpha has the potential to act via autocrine and paracrine mechanisms to contribute to the pathobiology of human pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225458     DOI: 10.1002/(sici)1097-0215(19990517)81:4<650::aid-ijc23>3.0.co;2-#

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

Review 1.  Chemokines and dendritic cell traffic.

Authors:  S Sozzani; P Allavena; A Vecchi; A Mantovani
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

2.  High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection.

Authors:  Xiangjiu Ding; Kexin Wang; Hui Wang; Guangyong Zhang; Yajing Liu; Qingyun Yang; Weijie Chen; Sanyuan Hu
Journal:  J Gastrointest Surg       Date:  2011-11-10       Impact factor: 3.452

Review 3.  Chemokines: new, key players in the pathobiology of pancreatic cancer.

Authors:  Karen E Hedin
Journal:  Int J Gastrointest Cancer       Date:  2002

4.  Intersecting pathways in inflammation and cancer: Hepatocellular carcinoma as a paradigm.

Authors:  Philip Y Wai; Paul C Kuo
Journal:  World J Clin Oncol       Date:  2012-02-10

5.  Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinoma.

Authors:  Xiao-Peng Zhang; Zhi-Juan Hu; Ai-Hong Meng; Guo-Chen Duan; Qing-Tao Zhao; Jing Yang
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

6.  Fusobacterium nucleatum and human beta-defensins modulate the release of antimicrobial chemokine CCL20/macrophage inflammatory protein 3α.

Authors:  Santosh K Ghosh; Sanhita Gupta; Bin Jiang; Aaron Weinberg
Journal:  Infect Immun       Date:  2011-09-12       Impact factor: 3.441

Review 7.  Chemokines in health and disease.

Authors:  Dayanidhi Raman; Tammy Sobolik-Delmaire; Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

8.  CCL20/CCR6 expression profile in pancreatic cancer.

Authors:  Claudia Rubie; Vilma Oliveira Frick; Pirus Ghadjar; Mathias Wagner; Henner Grimm; Benjamin Vicinus; Christoph Justinger; Stefan Graeber; Martin K Schilling
Journal:  J Transl Med       Date:  2010-05-10       Impact factor: 5.531

Review 9.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

10.  Interaction between CXCR4 and CCL20 pathways regulates tumor growth.

Authors:  Katia Beider; Michal Abraham; Michal Begin; Hanna Wald; Ido D Weiss; Ori Wald; Eli Pikarsky; Rinat Abramovitch; Evelyne Zeira; Eithan Galun; Arnon Nagler; Amnon Peled
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.